Bruker Corporation

Bruker Corporation, headquartered in Billerica, Massachusetts, is a globally leading, highly specialized provider of ultra-high-performance scientific instruments. Founded in 1960, Bruker absolutely dominates the most complex, technologically demanding niches of advanced structural research, molecular analysis, and applied industrial applications. Operating as a colossal enterprise with roughly 11,000 employees globally, Bruker generated roughly $3.5 billion in trailing 12-month revenue in 2026.

The company is the undisputed, absolute global market leader in Nuclear Magnetic Resonance (NMR) spectroscopy and highly advanced Electron Paramagnetic Resonance (EPR) spectroscopy, largely organized under its Bruker BioSpin division. These massive, superconducting magnetic instruments are absolutely essential for scientists attempting to decipher the highly complex, 3D atomic structures of large proteins and critical drug molecules.

Beyond NMR, Bruker is a massive powerhouse in highly advanced mass spectrometry, specialized X-ray diffraction, and complex atomic force microscopy across its BSI CALID and BSI Nano divisions.

In recent years, Bruker has aggressively and successfully expanded its profound footprint into the clinical diagnostics and spatial biology space. Most notably, their revolutionary MALDI Biotyper platform uses advanced mass spectrometry to rapidly, precisely, and cost-effectively identify microscopic bacterial and fungal pathogens in clinical microbiology labs, fundamentally replacing incredibly slow, traditional biochemical culturing methods. Further accelerating its push into multi-omics, Bruker has recently made significant strategic acquisitions, including PhenomeX for single-cell biology, Biognosys for proteomics, and assets from NanoString Technologies for spatial transcriptomics.

By continuously pushing the absolute extreme limits of what is physically measurable, Bruker heavily empowers elite scientists and frontline clinicians to make profound, paradigm-shifting discoveries across structural biology, multi-omics, and infectious disease diagnostics.